February 5, 2010 – 12:17 am

The BD Physioject Disposable AutoInjector received very high marks from patient groups for usability and accuracy.
The state of the market for self-injection devices is healthy and growing at a steady clip, noted Joel Cotten, European Product Manager/Marketing, BD Medical – Pharmaceutical Systems during the BIOMEDevice Europe conference in Paris. Currently, 15% of all injections are performed by the patient, he told attendees, a percentage that will continue to rise.
“With the exception of cancer and vaccine treatments, most drugs in the pipeline will be delivered via self-injection systems,” said Cotten. Acknowledging the inherent difficulty in assigning a real value to a device that is often developed and sold in tandem with a drug, he estimated that the market for self-injection systems was upwards of US$1 billion in 2007 and that it would reach US$2 billion by 2012. Read more…
Posted in Drug delivery, medtechinsider | Add Comment span>